The DOI matches its Crossref record; 44 of the 44 references it cites were found in a registry or an index.
Annexin A1 Counteracts Chemokine-Induced Arterial Myeloid Cell Recruitment
Open accessAbstract
Rationale: Chemokine-controlled arterial leukocyte recruitment is a crucial process in atherosclerosis. Formyl peptide receptor 2 (FPR2) is a chemoattractant receptor that recognizes proinflammatory and proresolving ligands. The contribution of FPR2 and its proresolving ligand annexin A1 to atherosclerotic lesion formation is largely undefined. Objective: Because of the ambivalence of FPR2 ligands, we here investigate the role of FPR2 and its resolving ligand annexin A1 in atherogenesis. Methods and Results: Deletion of FPR2 or its ligand annexin A1 enhances atherosclerotic lesion formation, arterial myeloid cell adhesion, and recruitment. Mechanistically, we identify annexin A1 as an endogenous inhibitor of integrin activation evoked by the chemokines CCL5, CCL2, and CXCL1. Specifically, the annexin A1 fragment Ac2-26 counteracts conformational activation and clustering of integrins on myeloid cells evoked by CCL5, CCL2, and CXCL1 through inhibiting activation of the small GTPase Rap1. In vivo administration of Ac2-26 largely diminishes arterial recruitment of myeloid cells in a FPR2-dependent fashion. This effect is also observed in the presence of selective antagonists to CCR5, CCR2, or CXCR2, whereas Ac2-26 was without effect when all 3 chemokine receptors were antagonized simultaneously. Finally, repeated treatment with Ac2-26 reduces atherosclerotic lesion sizes and lesional macrophage accumulation. Conclusions: Instructing the annexin A1-FPR2 axis harbors a novel approach to target arterial leukocyte recruitment. With the ability of Ac2-26 to counteract integrin activation exerted by various chemokines, delivery of Ac2-26 may be superior in inhibition of arterial leukocyte recruitment when compared with blocking individual chemokine receptors.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“the increased atherosclerosis burden observed in Apoe−/−Anxa1−/− mice compared with Apoe−/− mice can be reduced by treatment with the annexin A1 mimetic peptide Ac2–26, whereas this treatment does not affect atherosclerotic lesion size in Apoe−/− mice lacking ALX/FPR2 (REF108).”
From Inflammation and its resolution in atherosclerosis: mediators and therapeutic opportunities (2019) · cites this paper as [108]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Atherosclerosis: current pathogenesis and therapeutic options
Weber, C., & Noels, H. (2011) · Nature Medicine · doi:10.1038/nm.2538 · Cited by 2,203
Self-citationLeukocyte Behavior in Atherosclerosis, Myocardial Infarction, and Heart Failure
Świrski, F. K., & Nahrendorf, M. (2013) · Science · doi:10.1126/science.1230719 · Cited by 1,121
Resolution of inflammation: an integrated view
Ortega‐Gómez, A., Perretti, M., & Soehnlein, O. (2013) · EMBO Molecular Medicine · doi:10.1002/emmm.201202382 · Cited by 776
Self-citationHyperlipidemia-triggered neutrophilia promotes early atherosclerosis
Drechsler, M., Megens, R. T. A., van Zandvoort, M., Weber, C., & Soehnlein, O. (2010) · Circulation · doi:10.1161/circulationaha.110.961714 · Cited by 698
Self-citationCombadière, C., Potteaux, S., Rodero, M. P., Simon, T., Pézard, A., Esposito, B., Merval, R., Proudfoot, A. E. I., Tedgui, A., & Mallat, Z. (2008) · Circulation · doi:10.1161/circulationaha.107.745091 · Cited by 696
Kempf, T., Zarbock, A., Widera, C., Butz, S., Stadtmann, A., Rossaint, J., Bolomini-Vittori, M., Korf-Klingebiel, M., Napp, L. C., Hansen, B., et al. (2011) · Nature Medicine · doi:10.1038/nm.2354 · Cited by 518
The Lipoxin Receptor ALX: Potent Ligand-Specific and Stereoselective Actions in Vivo
Chiang, N., Serhan, C. N., Dahlén, S., Drazen, J. M., Hay, D. W. P., Rovati, G. E., Shimizu, T., Yokomizo, T., & Brink, C. (2006) · Pharmacological Reviews · doi:10.1124/pr.58.3.4 · Cited by 464
MIGEOTTE, I., COMMUNI, D., & PARMENTIER, M. (2006) · Cytokine & Growth Factor Reviews · doi:10.1016/j.cytogfr.2006.09.009 · Cited by 457
Annexin I Is an Endogenous Ligand that Mediates Apoptotic Cell Engulfment
Arur, S., Uche, U. E., Rezaul, K., Fong, M., Scranton, V., Cowan, A. E., Mohler, W., & Han, D. K. (2003) · Developmental Cell · doi:10.1016/s1534-5807(03)00090-x · Cited by 434
Regulation of leukocyte recruitment by the long pentraxin PTX3
Deban, L., Russo, R. C., Sironi, M., Moalli, F., Scanziani, M., Zambelli, V., Cuccovillo, I., Bastone, A., Gobbi, M., Valentino, S., et al. (2010) · Nature Immunology · doi:10.1038/ni.1854 · Cited by 426
Cited by
Sorted by citations
Inflammation and its resolution in atherosclerosis: mediators and therapeutic opportunities
Bäck, M., Yurdagul, A., Tabas, I., Öörni, K., & Kovanen, P. T. (2019) · Nature Reviews Cardiology · doi:10.1038/s41569-019-0169-2 · Cited by 1,341
Macrophage Phenotype and Function in Different Stages of Atherosclerosis
Tabas, I., & Bornfeldt, K. E. (2016) · Circulation Research · doi:10.1161/circresaha.115.306256 · Cited by 1,121
Recent insights into the cellular biology of atherosclerosis
Tabas, I., García-Cardeña, G., & Owens, G. K. (2015) · Journal of Cell Biology · doi:10.1083/jcb.201412052 · Cited by 1,016
Targeting inflammation in atherosclerosis — from experimental insights to the clinic
Soehnlein, O., & Libby, P. (2021) · Nature Reviews Drug Discovery · doi:10.1038/s41573-021-00198-1 · Cited by 1,085
Self-citationNeutrophils as regulators of cardiovascular inflammation
Silvestre-Roig, C., Braster, Q., Ortega‐Gómez, A., & Soehnlein, O. (2020) · Nature Reviews Cardiology · doi:10.1038/s41569-019-0326-7 · Cited by 627
Self-citation
Metadata
- Authors
- Drechsler, M., de Jong, R., Rossaint, J., Viola, J. R., Leoni, G., Wang, J. M., Grommes, J., Hinkel, R., Kupatt, C., Weber, C., Döring, Y., Zarbock, A., & Soehnlein, O.
- Affiliations
- National Institutes of Health (US)
- From the Institute for Cardiovascular Prevention (IPEK), LMU Munich, Munich, Germany (M.D., R.d.J., J.R.V., G.L., J.G., C.W., Y.D., O.S.); Department of Pathology, Academic Medical Center (AMC), Amsterdam University, Amsterdam, The Netherlands (M.D., O.S.); Department of Anaesthesiology, University Münster, Münster, Germany (J.R., A.Z.); Max Planck Institute, Münster, Germany (J.R., A.Z.); Laboratory of Molecular Immunoregulation, NCI, Frederick, MD (J.M.W.); European Vascular Center Aachen...
- ORCID
- Venue
- Circulation Research
- Published
- 2015-02-27
- Volume
- 116
- Issue
- 5
- Pages
- 827-835
- ISSN
- 0009-7330 (ISSN-L)
- 1524-4571
- PMC
- PMC7751381
- OpenAlex
- W2100320418
- Cited by
- 150
- References
- 44
- Citations by year
- 2026: 3 · 2025: 16 · 2024: 8 · 2023: 8 · 2022: 22 · 2021: 14 · 2020: 9 · 2019: 15 · 2018: 17 · 2017: 9 · 2016: 17 · 2015: 12
- FWCI
- 5.79
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- Circulation Research (publishedVersion)
- Research Publications (Maastricht University) (publishedVersion, other-oa)
- PubMed (publishedVersion)
- PubMed Central (acceptedVersion)
- Data Archiving and Networked Services (DANS) (submittedVersion)
- mediaTUM (Technical University of Munich) (submittedVersion)
- RWTH Publications (RWTH Aachen) (submittedVersion)
- Research Publications (Maastricht University) (submittedVersion, other-oa)
- Funders
- National Institutes of Health
- National Cancer Institute (Z01BC010015)
- Topics
- Life Sciences › Immunology and Microbiology › Immunology › Atherosclerosis and Cardiovascular Diseases
- Health Sciences › Medicine › Oncology › Chemokine receptors and signaling
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › S100 Proteins and Annexins
- Keywords
- annexin A1, formyl peptide receptor 2, atherosclerosis, integrin activation, Rap1, chemokines, RANTES, MCP-1, CXCL1, Ac2-26, macrophage accumulation, chemokine receptor antagonists
- MeSH terms
- Animals, Aortic Diseases, Apolipoproteins E, Chemotaxis, Dietary Fats, Mice, Inbred C57BL, Peptides, Annexin A1, Mice, Knockout, Chemokine CCL2, Chemokine CCL5, Receptors, CCR5, rap1 GTP-Binding Proteins, Myeloid Cells, Receptors, Interleukin-8B, Receptors, Formyl Peptide, Atherosclerosis, Mice, Chemokine CXCL1, Receptors, CCR2
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
